Accelerate Diagnostics Return on Equity

Accelerate Diagnostics (AXDX) currently reports a ROE of 89.3%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore Accelerate Diagnostics's ROE history and peer comparisons.

Accelerate Diagnostics's ROE of 89.3% is higher than the Healthcare sector average of 29.33%. That is roughly 204.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Accelerate Diagnostics's current 89.3% should be judged against Healthcare norms (sector average: 29.33%) and against AXDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 89.3%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Accelerate Diagnostics, and consider following AXDX for alerts when major investors trade the stock.

Accelerate Diagnostics is classified in the Healthcare sector. On ROE, it currently shows 89.3% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AXDX with unrelated industries.